Encouraging findings suggest new avenues for treating liver disease in overweight Americans

A progressive form of non-alcoholic fatty liver disease known as non-alcoholic steatohepatitis (NASH) can lead to cirrhosis and all its complications. Two studies investigated the effectiveness of potential treatments for NASH, one assessing pentoxifyline, a commonly used TNF-alpha antagonist, as well as a separate analysis of pioglitazone, an insulin sensitizer, compared to vitamin E.

Read the whole article on Science Daily

More from Science Daily